Amgen Inc. (AMGN) Position Trimmed by NTV Asset Management LLC

NTV Asset Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,228 shares of the medical research company’s stock after selling 60 shares during the period. NTV Asset Management LLC’s holdings in Amgen were worth $1,933,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in AMGN. TrimTabs Asset Management LLC grew its holdings in Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares during the period. American Beacon Advisors Inc. acquired a new position in Amgen during the first quarter worth $106,000. Nelson Roberts Investment Advisors LLC acquired a new position in Amgen during the first quarter worth $121,000. Grove Bank & Trust grew its holdings in Amgen by 87.4% during the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after acquiring an additional 341 shares during the period. Finally, Enterprise Financial Services Corp grew its holdings in Amgen by 18.0% during the second quarter. Enterprise Financial Services Corp now owns 748 shares of the medical research company’s stock worth $129,000 after acquiring an additional 114 shares during the period. 78.20% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

A number of research analysts recently weighed in on AMGN shares. BMO Capital Markets reaffirmed a “market perform” rating and set a $198.00 price objective on shares of Amgen in a report on Thursday, October 26th. Cann reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 28th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Thursday, September 7th. Mizuho reaffirmed a “buy” rating and set a $198.00 price objective (up previously from $183.00) on shares of Amgen in a report on Thursday, September 28th. Finally, Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Thirteen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Amgen has an average rating of “Buy” and a consensus target price of $190.03.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/14/amgen-inc-amgn-position-trimmed-by-ntv-asset-management-llc.html.

Shares of Amgen Inc. (AMGN) opened at $171.50 on Tuesday. The company has a market capitalization of $125,110.70, a PE ratio of 13.70, a price-to-earnings-growth ratio of 2.50 and a beta of 1.37. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen Inc. has a 12 month low of $138.83 and a 12 month high of $191.10.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm’s revenue was down .7% on a year-over-year basis. During the same period in the prior year, the firm posted $3.02 earnings per share. sell-side analysts anticipate that Amgen Inc. will post 12.66 EPS for the current fiscal year.

Amgen announced that its board has initiated a share repurchase plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be paid a dividend of $1.15 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 annualized dividend and a yield of 2.68%. Amgen’s dividend payout ratio is presently 41.63%.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply